Galmed Pharmaceuticals Ltd. (NASDAQ:EOCN) Shares Shorted: Short Interest Down 46.7% in October

Posted by Doug Wharley on Oct 31st, 2026

Galmed Pharmaceuticals Ltd. (NASDAQ:EOCN – Get Free Report) was the recipient of a significant drop in short interest in the month of October. As of October 15th, there was short interest totaling 7,516 shares, a drop of 46.7% from the September 30th total of 14,112 shares. Based on an average daily volume of 9,029 shares, the short-interest ratio is presently 0.8 days. Approximately 0.9% of the shares of the stock are sold short.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Galmed Pharmaceuticals in a research note on Thursday, October 15th. One analyst has rated the stock with a Sell rating. Based on data from MarketBeat, the company has an average rating of “Sell”.

View Our Latest Report on Galmed Pharmaceuticals

Galmed Pharmaceuticals Trading Down 3.7%

NASDAQ:EOCN traded down $0.12 on Friday, hitting $3.10. 3,112 shares of the stock were exchanged, compared to its average volume of 7,782. The stock has a market cap of $3.23 million, a PE ratio of -0.20 and a beta of 0.66. The stock has a fifty day moving average of $4.05 and a 200-day moving average of $4.71. Galmed Pharmaceuticals has a fifty-two week low of $2.33 and a fifty-two week high of $12.32.

Galmed Pharmaceuticals (NASDAQ:EOCN – Get Free Report) last released its quarterly earnings data on Wednesday, September 2nd. The biopharmaceutical company reported ($2.86) earnings per share for the quarter, beating the consensus estimate of ($3.12) by $0.26.

About Galmed Pharmaceuticals

(Get Free Report)

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy.